Physician profile
John L Eckard
NPI 1083603187
$3,440.67
in general payments reported to CMS, 2019-2025
23 companies · $844 in 2025
The $844 reported for 2025 was more than what 79% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $519 · 2020: $148 · 2021: $120 · 2022: $412 · 2023: $565 · 2024: $833 · 2025: $844.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,152 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,151.94 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $442.51 | 2022-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $423.05 | 2019-2025 | Rexulti, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $389.27 | 2022-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Abbvie INC. | $323.18 | 2022-2025 | Vraylar |
| Sunovion Pharmaceuticals INC. | $317.03 | 2019-2022 | |
| Lundbeck LLC | $242.19 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| E.R. Squibb & Sons, L.L.C. | $226.93 | 2024-2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $215.19 | 2019-2025 | Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $141.56 | 2022-2025 | Caplyta |
| Allergan, INC. | $136.22 | 2019 | |
| Janssen Pharmaceuticals, INC | $106.08 | 2019-2023 | Spravato |
| Idorsia Pharmaceuticals US INC | $98.40 | 2022-2024 | Quviviq |
| Corium, LLC | $66.69 | 2022-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $65.32 | 2024 | |
| Neurocrine Biosciences, INC. | $53.75 | 2023-2024 | Ingrezza |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $47.56 | 2023-2024 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $43.11 | 2019-2025 | Trintellix |
| Neuronetics, INC. | $32.06 | 2019-2021 | |
| Collegium Pharmaceutical, INC. | $15.96 | 2025 | Jornay Pm |
| Jazz Pharmaceuticals INC. | $15.02 | 2021 | |
| Avanir Pharmaceuticals, INC. | $14.28 | 2019 | |
| Adlon Therapeutics L.P. | $13.06 | 2019 | |
| Alfasigma USA, INC. | $12.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Eckard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.